Study suggests that genomic profiling may help identify risk for hyper-progression after immunotherapy SAN DIEGO, CA – May 4, 2017 – UCSD oncologist and CureMatch Co-Founder Dr. Razelle Kurzrock and colleagues have published a study in the journal Clinical Cancer Research investigating “hyper-progressors.” Hyper-progressors are patients who unexpectedly fail immunotherapy treatment within 2 months, while also experiencing rapid […]
This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.
Otherwise, you will be redirected to the institutional part of this website.
Thank you for your understanding.